Clinical Trial

Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2025 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical study aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of HL-003 tablets in healthy subjects. It is conducted in two sequential clinical phases: single-dose and multiple-dose escalation.
Trial Details
NCT Number NCT06867393
Lead Sponsor Shanghai Kechow Pharma, Inc.
Conditions Healthy Subjects
Enrollment 52 participants
Start Date 2025-02-28
Primary Completion 2025-08 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-03-10